Pall (PLL) to Acquire Biotech Drugs Analytical Systems Firm ForteBio
Tweet
Share
E-mailGet Alerts PLL Hot Sheet
Join SI Premium – FREE
Pall Corporation (NYSE: PLL), has entered into a definitive merger agreement to acquire ForteBio, Inc.
The transaction is expected to close by February of 2012. Terms of the deal were not disclosed. Upon closing, ForteBio will become a wholly-owned subsidiary of Pall Corp. In the short term, the impact to Pall’s results of operations will be immaterial. Completion of the merger is subject to certain customary closing conditions.
ForteBio is a provider of advanced analytical systems that accelerate the discovery and development of biotech drugs.
The transaction is expected to close by February of 2012. Terms of the deal were not disclosed. Upon closing, ForteBio will become a wholly-owned subsidiary of Pall Corp. In the short term, the impact to Pall’s results of operations will be immaterial. Completion of the merger is subject to certain customary closing conditions.
ForteBio is a provider of advanced analytical systems that accelerate the discovery and development of biotech drugs.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Real and RE/MAX Holdings receive court approval for merger
- Trustar Bank to acquire Forbright Bank branches for $750M in deposits
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
